Effect of cyproterone acetate on pituitary-adrenocortical function in man.
Recent literature (1973-1976) suggests suppression of pituitary-adrenal function in patients (eg with pubertas praecox) who are treated with cyproterone acetate in high doses for prolonged periods. Therefore we investigated in our metabolic ward the effects of administration of 200 mg cyproterone acetate per day during 20 days to 4 healthy male volunteers. Baseline plasma cortisol and ACTH levels, repeated diurnal plasma cortisol and ACTH profiles and the results of tetracosactide (Synacthen) stimulation tests and single-dose metyrapone (Metopiron) tests proved to be comparable before, during and after treatment. Moreover, a slight gradual increase in urinary cortisol excretion during the observation period indicated that cyproterone acetate in the given dose during 20 days certainly does not reduce the pituitary-adrenal function of 4 healthy male volunteers. Long-term administration (during 1 to 7 years) of the combination of cyproterone acetate and ethinyloestradiol did not suppress serum levels of cortisol, prolactin, thyroxine and TSH in 18 female patients with hirsutism and/or acne.
D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000494:pharmacology; D000328:Adult; D002940:Circadian Rhythm; D003366:Cosyntropin / Q000494:pharmacology; D003534:Cyproterone / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008797:Metyrapone / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood; D013963:Thyroid Hormones / Q000097:blood
D013963:Thyroid Hormones; D003366:Cosyntropin; D013739:Testosterone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D003534:Cyproterone; D006854:Hydrocortisone; D008797:Metyrapone